Abcuro secured $66 million to pursue a new development path in inclusion body myositis (IBM), a rare inflammatory disorder with no approved drugs. The company said it will use the capital to support a Phase 2/3 study designed to generate data that could underpin a biologics license application. Abcuro previously ran a Phase 2/3 program earlier this year, which did not succeed overall, though the company reported positive trends in patients with less severe disease. The new effort targets a renewed clinical strategy around that signal. The financing underscores continued investor appetite for rare-disease assets where companies believe trial enrichment and subgroup effects can change regulatory outcomes.